Histone Deacetylase Inhibitors Increase p27Kip1 by Affecting Its Ubiquitin-Dependent Degradation through Skp2 Downregulation

Oxidative Medicine and Cellular Longevity

Volumn 2016, Issue , 2016, Pages

  Borriello, Adriana ^a   Naviglio, Silvio ^a   Bencivenga, Debora ^a   Caldarelli, Ilaria ^a   Tramontano, Annunziata ^a   Speranza, Maria Carmela ^a   Stampone, Emanuela ^a   Sapio, Luigi ^a   Negri, Aide ^b   Oliva, Adriana ^a   Sinisi, Antonio Agostino ^a   Spina, Annamaria ^a   Della Ragione, Fulvio ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CELL DEATH; ENZYME INHIBITION; GENE EXPRESSION;

ANTI-PROLIFERATIVE ACTIVITIES; CELLULAR RESPONSE; CYCLIN-DEPENDENT KINASE INHIBITORS; DOWN-REGULATION; HISTONE DEACETYLASE INHIBITOR; PHARMACOLOGICALLY ACTIVE COMPOUNDS; POST-TRANSLATIONAL MODIFICATIONS; PROTEIN DEGRADATION;

PROTEINS;

CYCLIN DEPENDENT KINASE INHIBITOR 1B; HISTONE DEACETYLASE INHIBITOR; S PHASE KINASE ASSOCIATED PROTEIN 2; UBIQUITIN; UBIQUITIN PROTEIN LIGASE E3; CDKN1B PROTEIN, HUMAN; S PHASE KINASE ASSOCIATED PROTEIN; TUMOR PROTEIN;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN PROCESSING; PROTEIN STABILITY; UBIQUITINATION; BIOSYNTHESIS; CACO-2 CELL LINE; GENE EXPRESSION REGULATION; GENETICS; HELA CELL LINE; K-562 CELL LINE; METABOLISM; NEOPLASM;

CACO-2 CELLS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HELA CELLS; HISTONE DEACETYLASE INHIBITORS; HUMANS; K562 CELLS; NEOPLASM PROTEINS; NEOPLASMS; PROTEOLYSIS; S-PHASE KINASE-ASSOCIATED PROTEINS;

EID: 84949238554     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2016/2481865     Document Type: Article

References (64)

1. S. L. Berger, "The complex language of chromatin regulation during transcription, " Nature, vol. 447, no. 7143, pp. 407-412, 2007.
2. T. Kouzarides, "Chromatin modifications and their function, " Cell, vol. 128, no. 4, pp. 693-705, 2007.
3. M. A. Dawson and T. Kouzarides, "Cancer epigenetics: from mechanism to therapy, " Cell, vol. 150, no. 1, pp. 12-27, 2012.
4. K. J. Falkenberg and R. W. Johnstone, "Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders, " Nature Reviews Drug Discovery, vol. 13, no. 9, pp. 673-691, 2014.
5. H. A. Tissenbaum and L. Guarente, "Increased dosage of a sir-2 gene extends lifespan in Caenorhabditis elegans, " Nature, vol. 410, no. 6825, pp. 227-230, 2001.
6. M. A. Dawson, T. Kouzarides, and B. J. P. Huntly, "Targeting epigenetic readers in cancer, " The New England Journal of Medicine, vol. 367, no. 7, pp. 647-657, 2012.
7. A. C. West and R. W. Johnstone, "New and emerging HDAC inhibitors for cancer treatment, "The Journal of Clinical Investigation, vol. 124, no. 1, pp. 30-39, 2014.
8. L. Staiano-Coico, M. Steinberg, and P. J. Higgins, "Epidermal cell-shape regulation and subpopulation kinetics during butyrate-induced terminal maturation of normal and SV40-transformed human keratinocytes: epithelial models of differentiation therapy, " International Journal of Cancer, vol. 46, no. 4, pp. 733-738, 1990.
9. A. Hague, A. M. Manning, K. A. Hanlon, L. I. Huschtscha, D. Hart, and C. Paraskeva, "Sodium butyrate induces apoptosis in human colonic tumour cell lines in a p53-independent pathway: implications for the possible role of dietary fibre in the prevention of large-bowel cancer, " International Journal of Cancer, vol. 55, no. 3, pp. 498-505, 1993.
10. B. G. Heerdt, M. A. Houston, and L. H. Augenlicht, "Potentiation by specific short-chain fatty acids of differentiation and apoptosis in human colonic carcinoma cell lines, " Cancer Research, vol. 54, no. 12, pp. 3288-3293, 1994.
11. E. C. Aguilar, A. J. Leonel, L. G. Teixeira et al., "Butyrate impairs atherogenesis by reducing plaque inflammation and vulnerability and decreasing NFB activation, " Nutrition, Metabolism and Cardiovascular Diseases, vol. 24, no. 6, pp. 606-613, 2014.
12. S. P. Perrine, M. F. Greene, and D. V. Faller, "Delay in the fetal globin switch in infants of diabetic mothers, " The New England Journal of Medicine, vol. 312, no. 6, pp. 334-338, 1985.
13. S. P. Perrine, A. Rudolph, D. V. Faller et al., "Butyrate infusions in the ovine fetus delay the biologic clock for globin gene switching, " Proceedings of the National Academy of Sciences of theUnited States of America, vol. 85, no. 22, pp. 8540-8542, 1988.
14. S. P. Perrine, G. D. Ginder, D. V. Faller et al., "Ashort-termtrial of butyrate to stimulate fetal-globin-gene expression in the -globin disorders, "TheNewEngland Journal ofMedicine, vol. 328, no. 2, pp. 81-86, 1993.
15. D. V. Faller and S. P. Perrine, "Butyrate in the treatment of sickle cell disease and -thalassemia, " CurrentOpinion inHematology, vol. 2, no. 2, pp. 109-117, 1995.
16. S. P. Perrine, O. Hermine, T. Small et al., "A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies, " Blood, vol. 109, no. 6, pp. 2571-2578, 2007.
17. V. M. Richon, Y. Webb, R. Merger et al., "Second generation hybrid polar compounds are potent inducers of transformed cell differentiation, " Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 12, pp. 5705-5708, 1996.
18. M. Göttlicher, S. Minucci, P. Zhu et al., "Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells, " The EMBO Journal, vol. 20, no. 24, pp. 6969-6978, 2001.
19. A. Besson, S. F. Dowdy, and J. M. Roberts, "CDK inhibitors: cell cycle regulators and beyond, " Developmental Cell, vol. 14, no. 2, pp. 159-169, 2008.
20. A. Borriello, V. Cucciolla, A. Oliva, V. Zappia, and F. Della Ragione, "p27Kip1 metabolism: A fascinating labyrinth, " Cell Cycle, vol. 6, no. 9, pp. 1053-1061, 2007.
21. A. Borriello, D. Bencivenga, M. Criscuolo et al., "Targeting p27Kip1 protein: its relevance in the therapy of human cancer, " Expert Opinion on Therapeutic Targets, vol. 15, no. 6, pp. 677-693, 2011.
22. F. Della Ragione, V. Cucciolla, V. Criniti, S. Indaco, A. Borriello, and V. Zappia, "211 gene expression is modulated by Egr1: A novel regulatory mechanism involved in the resveratrol antiproliferative effect, " Journal of Biological Chemistry, vol. 278, no. 26, pp. 23360-23368, 2003.
23. A. Borriello, V. Della Pietra, M. Criscuolo et al., "p27Kip1 accumulation is associated with retinoic-induced neuroblastoma differentiation: evidence of a decreased proteasome-dependent degradation, " Oncogene, vol. 19, no. 1, pp. 51-60, 2000.
24. V. Cucciolla, A. Borriello, M. Criscuolo et al., "Histone deacetylase inhibitors upregulate p57Kip2 level by enhancing its expression through Sp1 transcription factor, " Carcinogenesis, vol. 29, no. 3, pp. 560-567, 2008.
25. D. Bencivenga, A. Tramontano, A. Borgia et al., "p27Kip1 serine 10 phosphorylation determines its metabolism and interaction with cyclin-dependent kinases, " Cell Cycle, vol. 13, no. 23, pp. 3768-3782, 2014.
26. A. Borriello, V. Cucciolla, M. Criscuolo et al., "Retinoic acid induces p27 Kip1 nuclear accumulation by modulating its phosphorylation, " Cancer Research, vol. 66, no. 8, pp. 4240-4248, 2006.
27. M. Ocker and R. Schneider-Stock, "Histone deacetylase inhibitors: signalling towards p21cip1/waf1, " International Journal of Biochemistry and Cell Biology, vol. 39, no. 7-8, pp. 1367-1374, 2007.
28. A. Borriello, I. Caldarelli, D. Bencivenga et al., "p57Kip2 and cancer: Time for a critical appraisal, "Molecular Cancer Research, vol. 9, no. 10, pp. 1269-1284, 2011.
29. Q. Wang, Y. Zhou, X. Wang, and B. M. Evers, "p27Kip1 nuclear localization and cyclin-dependent kinase inhibitory activity are regulated by glycogen synthase kinase-3 in human colon cancer cells, " Cell Death and Differentiation, vol. 15, no. 5, pp. 908-919, 2008.
30. N. Uehara, K. Yoshizawa, and A. Tsubura, "Vorinostat enhances protein stability of p27 and p21 through negative regulation of Skp2 and Cks1 in human breast cancer cells, " Oncology Reports, vol. 28, no. 1, pp. 105-110, 2012.
31. W. Jiang, Q. Guo, J. Wu et al., "Dual effects of sodium butyrate on hepatocellular carcinoma cells, " Molecular Biology Reports, vol. 39, no. 5, pp. 6235-6242, 2012.
32. E. S. Yang and K. L. Burnstein, "Vitamin D inhibits G1 to S progression in LNCaP prostate cancer cells through p27Kip1 stabilization and Cdk2 mislocalization to the cytoplasm, " The Journal of Biological Chemistry, vol. 278, no. 47, pp. 46862-46868, 2003.
33. T. Bashir, N. V. Dorrello, V. Amado, D. Guardavaccaro, and M. Pagano, "Control of the SCFSkp2?Cks1 ubiquitin ligase by the APC/CCdh1 ubiquitin ligase, " Nature, vol. 428, no. 6979, pp. 190-193, 2004.
34. W. Wei, N. G. Ayad, Y. Wan, G.-J. Zhang, M. W. Kirschner, andW. G. Kaelin Jr., "Degradation of the SCF component Skp2 in cell-cycle phase G1 by the anaphase-promoting complex, " Nature, vol. 428, no. 6979, pp. 194-198, 2004.
35. H.-K. Lin, G. Wang, Z. Chen et al., "Phosphorylationdependent regulation of cytosolic localization and oncogenic function of Skp2 by Akt/PKB, " Nature Cell Biology, vol. 11, no. 4, pp. 420-432, 2009.
36. D. Gao, H. Inuzuka, A. Tseng, R. Y. Chin, A. Toker, andW. Wei, "Phosphorylation by Akt1 promotes cytoplasmic localization of Skp2 and impairs APCCdh1-mediated Skp2 destruction, " Nature Cell Biology, vol. 11, no. 4, pp. 397-408, 2009.
37. G. Rodier, P. Coulombe, P.-L. Tanguay, C. Boutonnet, and S. Meloche, "Phosphorylation of Skp2 regulated by CDK2 and Cdc14B protects it from degradation by APCCdh1 in G1 phase, " The EMBO Journal, vol. 27, no. 4, pp. 679-691, 2008.
38. S. Cantoni, M. Galletti, F. Zambelli et al., "Sodium butyrate inhibits platelet-derived growth factor-induced proliferation and migration in pulmonary artery smooth muscle cells through Akt inhibition, " FEBS Journal, vol. 280, no. 9, pp. 2042-2055, 2013.
39. C.-S. Chen, S.-C. Weng, P.-H. Tseng, H.-P. Lin, and C.-S. Chen, "Histone acetylation-independent effect of histone deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1 complexes, "The Journal of Biological Chemistry, vol. 280, no. 46, pp. 38879-38887, 2005.
40. R. V. Lloyd, L. A. Erickson, L. Jin et al., "p27kip1: A multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers, " The American Journal of Pathology, vol. 154, no. 2, pp. 313-323, 1999.
41. R. L. Piekarz, R. Robey, V. Sandor et al., "Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: A case report, " Blood, vol. 98, no. 9, pp. 2865-2868, 2001.
42. J. E. Bolden, M. J. Peart, and R. W. Johnstone, "Anticancer activities of histone deacetylase inhibitors, " Nature Reviews Drug Discovery, vol. 5, no. 9, pp. 769-784, 2006.
43. E. A. Olsen, Y. H. Kim, T. M. Kuzel et al., "Phase IIBmulticenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous t-cell lymphoma, " Journal of Clinical Oncology, vol. 25, no. 21, pp. 3109-3115, 2007.
44. S. J. Whittaker, M.-F. Demierre, E. J. Kim et al., "Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma, " Journal of Clinical Oncology, vol. 28, no. 29, pp. 4485-4491, 2010.
45. R. L. Piekarz, R. Frye, M. Turner et al., "Phase II multiinstitutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma, " Journal of Clinical Oncology, vol. 27, no. 32, pp. 5410-5417, 2009.
46. N. A. Barlev, L. Liu, N. H. Chehab et al., "Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases, " Molecular Cell, vol. 8, no. 6, pp. 1243-1254, 2001.
47. F. Faiola, X. Liu, S. Lo et al., "Dual regulation of c-Myc by p300 via acetylation-dependent control ofMyc protein turnover and coactivation of Myc-induced transcription, " Molecular and Cellular Biology, vol. 25, no. 23, pp. 10220-10234, 2005.
48. H. Matsuzaki, H. Daitoku, M. Hatta, H. Aoyama, K. Yoshimochi, and A. Fukamizu, "Acetylation of Foxo1 alters its DNAbinding ability and sensitivity to phosphorylation, " Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 32, pp. 11278-11283, 2005.
49. J. Tsihlias, L. Kapusta, and J. Slingerland, "The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer, " Annual Review ofMedicine, vol. 50, pp. 401-423, 1999.
50. A. Sgambato, A. Cittadini, B. Faraglia, and I. B. Weinstein, "Multiple functions of p27(Kip1) and its alterations in tumor cells: A review, " Journal of Cellular Physiology, vol. 183, no. 1, pp. 18-27, 2000.
51. M. Pagano, S. W. Tam, A. M. Theodoras et al., "Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27, " Science, vol. 269, no. 5224, pp. 682-685, 1995.
52. A. C. Carrano, E. Eytan, A. Hershko, and M. Pagano, "SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27, " Nature Cell Biology, vol. 1, no. 4, pp. 193-199, 1999.
53. H. Sutterlüty, E. Chatelain, A. Marti et al., "p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells, " Nature Cell Biology, vol. 1, no. 4, pp. 207-214, 1999.
54. C. Spruck, H. Strohmaier, M. Watson et al., "A CDKindependent function of mammalian Cks1: Targeting of SCFSkp2 to the CDK inhibitor p27Kip1, " Molecular Cell, vol. 7, no. 3, pp. 639-650, 2001.
55. T. Hara, T. Kamura, K. Nakayama, K. Oshikawa, S. Hatakeyama, and K.-I. Nakayama, "Degradation of p27Kip1 at the G0-G1 transition mediated by a Skp2-independent ubiquitination pathway, " The Journal of Biological Chemistry, vol. 276, no. 52, pp. 48937-48943, 2001.
56. N. P. Malek, H. Sundberg, S. McGrew, K. Nakayama, T. R. Kyriakidis, and J. M. Roberts, "A mouse knock-in model exposes sequential proteolytic pathways that regulate p27Kip1 in G1 and S phase, " Nature, vol. 413, no. 6853, pp. 323-327, 2001.
57. T. Kamura, T. Hara, M. Matsumoto et al., "Cytoplasmic ubiquitin ligase KPC regulates proteolysis of p27(Kip1) at G1 phase, " Nature Cell Biology, vol. 6, no. 12, pp. 1229-1235, 2004.
58. S. Kotoshibai, T. Kamura, T. Hara, N. Ishida, and K. I. Nakayama, "Molecular dissection of the interaction between p27 and Kip1 ubiquitylation-promoting complex, the ubiquitin ligase that regulates proteolysis of p27 in G1 phase, " The Journal of Biological Chemistry, vol. 280, no. 18, pp. 17694-17700, 2005.
59. A. Besson, M. Gurian-West, X. Chen, K. S. Kelly-Spratt, C. J. Kemp, and J. M. Roberts, "A pathway in quiescent cells that controls p271 stability, subcellular localization, and tumor suppression, " Genes and Development, vol. 20, no. 1, pp. 47-64, 2006.
60. H. Imaki, K. Nakayama, S. Delehouzee et al., "Cell cycledependent regulation of the Skp2 promoter by GA-binding protein, " Cancer Research, vol. 63, no. 15, pp. 4607-4613, 2003.
61. H. Inuzuka, D. Gao, L. W. S. Finley et al., "Acetylationdependent regulation of Skp2 function, " Cell, vol. 150, no. 1, pp. 179-193, 2012.
62. D. Frescas and M. Pagano, "Deregulated proteolysis by the Fbox proteins SKP2 and -TrCP: Tipping the scales of cancer, " Nature Reviews Cancer, vol. 8, no. 6, pp. 438-449, 2008.
63. D. D. Hershko, "Oncogenic properties and prognostic implications of the ubiquitin ligase Skp2 in cancer, " Cancer, vol. 112, no. 7, pp. 1415-1424, 2008.
64. O. H. Krämer, P. Zhu, H. P. Ostendorff et al., "The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2, " The EMBO Journal, vol. 22, no. 13, pp. 3411-3420, 2003.